share_log

Regeneron Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Regeneron Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

再生元製藥公司 | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/01 19:21

Moomoo AI 已提取核心訊息

Regeneron Pharmaceuticals reported robust Q2 2024 financial results, with total revenues increasing 12% to $3.55 billion and net income rising 48% to $1.43 billion. The growth was driven by strong performance of key products, with U.S. EYLEA HD and EYLEA combined net sales reaching $1.53 billion, while global Dupixent sales grew 27% to $3.56 billion.Research and development expenses rose 11% to $1.2 billion as the company advanced multiple clinical programs. The company maintained a strong balance sheet with $17.5 billion in cash and marketable securities as of June 30, 2024. Operating expenses increased 16% to $2.48 billion, reflecting investments in commercial capabilities and product launches.Looking ahead, Regeneron faces both opportunities and challenges, including potential biosimilar competition for EYLEA following U.S. regulatory exclusivity expiration in May 2024. The company continues to advance its pipeline with multiple late-stage clinical trials while expanding its commercial presence globally, particularly for products like Libtayo and Dupixent.
Regeneron Pharmaceuticals reported robust Q2 2024 financial results, with total revenues increasing 12% to $3.55 billion and net income rising 48% to $1.43 billion. The growth was driven by strong performance of key products, with U.S. EYLEA HD and EYLEA combined net sales reaching $1.53 billion, while global Dupixent sales grew 27% to $3.56 billion.Research and development expenses rose 11% to $1.2 billion as the company advanced multiple clinical programs. The company maintained a strong balance sheet with $17.5 billion in cash and marketable securities as of June 30, 2024. Operating expenses increased 16% to $2.48 billion, reflecting investments in commercial capabilities and product launches.Looking ahead, Regeneron faces both opportunities and challenges, including potential biosimilar competition for EYLEA following U.S. regulatory exclusivity expiration in May 2024. The company continues to advance its pipeline with multiple late-stage clinical trials while expanding its commercial presence globally, particularly for products like Libtayo and Dupixent.
再生元製藥公司公佈了2024年第二季度的財務業績，整體收入增長12%，達到35.5億元，凈利潤增長48%，達到14.3億元。增長主要得益於關鍵產品的強勁表現，美國EYLEA HD和EYLEA的淨銷售額達到15.3億元，而全球Dupixent的銷售額增長了27%，達到35.6億元。研究和開發費用增長了11%，達到12億元，因爲公司推進了多項臨牀項目。截止到2024年6月30日，公司保持了強勁的資產負債表，現金和可交易證券達到175億元。營業費用增加了16%，達到24.8億元，反映了對商業能力和產品發佈的投資。展望未來，再生元面臨着機遇和挑戰，包括在2024年5月美國監管獨佔期結束後，EYLEA可能面臨仿製藥競爭。公司繼續推進其綜合管道，多項晚期臨牀試驗正在進行，同時在全球範圍內擴大其商業存在，特別是針對Libtayo和Dupixent等產品。
再生元製藥公司公佈了2024年第二季度的財務業績，整體收入增長12%，達到35.5億元，凈利潤增長48%，達到14.3億元。增長主要得益於關鍵產品的強勁表現，美國EYLEA HD和EYLEA的淨銷售額達到15.3億元，而全球Dupixent的銷售額增長了27%，達到35.6億元。研究和開發費用增長了11%，達到12億元，因爲公司推進了多項臨牀項目。截止到2024年6月30日，公司保持了強勁的資產負債表，現金和可交易證券達到175億元。營業費用增加了16%，達到24.8億元，反映了對商業能力和產品發佈的投資。展望未來，再生元面臨着機遇和挑戰，包括在2024年5月美國監管獨佔期結束後，EYLEA可能面臨仿製藥競爭。公司繼續推進其綜合管道，多項晚期臨牀試驗正在進行，同時在全球範圍內擴大其商業存在，特別是針對Libtayo和Dupixent等產品。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Portage Biotech
    PRTG
    -- 9.600
    萊斯康製藥
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日